source
- FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billionThe U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company. Private-equity firm EQT announced a definit…
- US Treasury drafts rules to curb American investment in Chinese biotech firmsThe Treasury Department has released draft regulations that would impose broad restrictions on U.S. companies and venture capital firms investing in or acquiring drug and biotechnology assets linke…